GO-203-2C
- Generic Name
- GO-203-2C
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C89H170N52O20S2
- CAS Number
- 1469735-88-3
- Unique Ingredient Identifier
- 5YSY733NA3
- Background
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
- Associated Conditions
- -
- Associated Therapies
- -
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
- Conditions
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT02658396
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02204085
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Genus Oncology, LLC
- Target Recruit Count
- 23
- Registration Number
- NCT01279603
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธTGen Clinical Research Service, Scottsdale, Arizona, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.